NINDS encourages applications for preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (IDD). This announcement is made together with 2 other NIH components.
Over the past several decades, major advances have been made in finding the genetic and environmental causes of many forms of IDD in children and adults. Historically, treatment has focused on alleviating symptoms. More recently, however, a great deal has been learned about the mechanisms and pathways that underlie such disorders. As promising therapeutics move to preclinical (animal) testing, there is a critical need for sensitive, reliable, and valid outcome measures and/or surrogate markers in model organisms, particularly measures that can predict safety, toxicity, and efficacy in human trials. The goal of this announcement is to accelerate and improve the preclinical testing of candidate treatments and therapeutic compounds in order to move promising new drug therapies to clinical trials.
Potential applicants should contact Dr. Laura Mamounas, program director, Neurogenetics Cluster, NINDS, at 301-496-5745 or firstname.lastname@example.org. For more information visit http://grants.nih.gov/grants/guide/pa-files/PAR-11-038.html.